WhatPeptide

DSIP

An endogenous neuropeptide candidate historically explored for sleep regulation and stress-response modulation. Placed on FDA Category 2 list (September 29, 2023) as 'Emideltide (DSIP).'

Preliminary evidence FDA Category 2 Sleep

Written by WhatPeptide Editorial Team · Last updated 2026-03-17

FDA Category 2 — compounding availability may be limited.

Half-life

Very short plasma half-life

Dosage range

100-300 mcg before sleep (research context)

Administration

Intranasal

Research level

Preliminary

How DSIP works

DSIP is hypothesized to influence sleep architecture through interactions with hypothalamic and pituitary signaling networks. Studies suggest potential stress-axis and neurotransmitter effects, but reproducibility has been inconsistent. Contemporary evidence is preliminary and largely non-definitive.

Also known as: Delta Sleep-Inducing Peptide

Research relevance

Sleep & Relaxation
Moderate relevance 60
Recovery & Healing
Some relevance 40
Cognition & Focus
Some relevance 30
Anti-Aging & Longevity
Some relevance 20
Immune Support
Some relevance 20

Side effects & safety

Grogginess Headache Lightheadedness

Contraindications

Pregnancy
Use with sedatives requires caution

Consult a healthcare provider before use if any of these apply to you.

Key studies

FAQ

What is DSIP? +
An endogenous neuropeptide candidate historically explored for sleep regulation and stress-response modulation. Placed on FDA Category 2 list (September 29, 2023) as 'Emideltide (DSIP).' Its mechanism of action is based on preliminary or early-stage research.
What is DSIP researched for? +
DSIP has the strongest research relevance for Sleep & Relaxation, Recovery & Healing, Cognition & Focus. Evidence is based on preliminary or early-stage research.
What are the side effects of DSIP? +
Reported side effects include Grogginess, Headache, Lightheadedness. Key contraindications: Pregnancy; Use with sedatives requires caution.
Is DSIP FDA approved? +
DSIP is classified as FDA Category 2, meaning compounding availability may be limited.
How is DSIP administered? +
DSIP is typically administered via nasal route. Researched dosage range: 100-300 mcg before sleep (research context). Half-life: Very short plasma half-life.

Explore similar peptides

CJC-1295

Moderate evidence

GH Secretagogue

A modified GHRH analog designed to prolong endogenous GH pulse support through albumin binding (DAC form). Originally placed on FDA Category 2 list (September 2023), then removed September 27, 2024 when the nominator withdrew. FDA still lists it under 'Other bulk drug substances that may present significant safety risks.' Regulatory status remains uncertain.

Ipamorelin

Moderate evidence

Growth Hormone Releasing Peptide

A selective ghrelin-receptor agonist studied for stimulating GH release with less prolactin/cortisol impact than older GHRPs. Originally placed on FDA Category 2 list (September 2023), then removed September 27, 2024 when the nominator withdrew. FDA still lists it under 'Other bulk drug substances that may present significant safety risks.' Regulatory status remains uncertain.

MK-677

Moderate evidence

GH Secretagogue

An oral non-peptide ghrelin receptor agonist often discussed with GH peptides due to GH/IGF-1 stimulating effects. Placed on FDA Category 2 list (September 29, 2023) as 'Ibutamoren mesylate.'

Epithalon

Preliminary evidence

Telomere

A synthetic tetrapeptide associated with pineal peptide research and putative telomerase-related aging hypotheses. Placed on FDA Category 2 list (September 29, 2023) as 'Epitalon.'